Related Experiment Video
Updated: Jul 29, 2025
11:25
Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
Published on: July 11, 2014
33.8K
Valproate-Induced Metabolic Syndrome
Natalia A Shnayder1,2, Violetta V Grechkina1, Vera V Trefilova1,3
1Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia.
Biomedicines
|May 27, 2023
Summary
Long-term use of valproic acid (VPA) can lead to metabolic syndrome (MetS). This review explores blood and urinary biomarkers for preventing and diagnosing VPA-induced MetS in patients with neurological and psychiatric conditions.
Area of Science:
- Pharmacology and Toxicology
- Metabolic Disorders
- Biomarker Discovery
Background:
- Valproic acid (VPA) and its salts are widely prescribed psychotropic medications.
- Long-term VPA use is associated with adverse drug reactions (ADRs), notably metabolic syndrome (MetS).
- MetS is a cluster of conditions including obesity, hypertension, hyperglycemia, dyslipidemia, and low HDL cholesterol.
Purpose of the Study:
- To review current research on blood and urinary biomarkers for VPA-induced MetS (VPA-MetS).
- To highlight the need for an updated, multidisciplinary approach to VPA-MetS prevention and diagnosis.
- To explore the potential of metabolic biomarkers in personalized medicine strategies for VPA-MetS.
Main Methods:
- Systematic review of studies investigating blood (serum, plasma) and urinary biomarkers.
- Analysis of existing literature on VPA-MetS prevalence and risk factors.
- Synthesis of findings related to diagnostic and predictive biomarker potential.
Main Results:
- Identification of various blood and urinary metabolic biomarkers associated with VPA-MetS.
- Evidence suggesting that biomarkers can aid in early detection and risk stratification.
- Discussion of the heterogeneity in VPA-MetS presentation and the need for personalized approaches.
Conclusions:
- Metabolic biomarkers hold promise for developing personalized strategies for VPA-MetS prevention and diagnosis.
- A multidisciplinary approach is crucial for managing VPA-MetS in patients with neurological, psychiatric, and addiction disorders.
- Further research into specific biomarkers is warranted to refine diagnostic and therapeutic interventions.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
474
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
474
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
215
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
215
01:20Antiepileptic Drugs: Potassium Channel Activators
221
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
221
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
249
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
249
01:14Antiepileptic Drugs: Glutamate Antagonists
435
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
435